In a recent study, researchers designed substituted spiro indolin-1,2-diazepine derivatives ‘5a–v’ with cholinesterase inhibitory activities as anti-Alzheimer’s disease agents.
Denali reports a PhII ALS fail as RIPK1 deal with Sanofi hits another bump
Sanofi and Denali Therapeutics’ partnership ran into yet another stumbling block after their ALS program failed a Phase II study. DNL788 did not achieve the
February 17, 2024